Nanotechnology is all about understanding issues on the smallest unit of measurement doable. Just like the oceans, we’re solely starting to discover how life works at a mobile stage. Subsequent-generation sequencing instruments from Illumina $ILMN have allowed every kind of genomics firms to proliferate with some winners and losers. Each spend cash on sequencing instruments which is why we discover the Illumina razor-blade story so compelling. It’s a choose and shovel play on the expansion of genomics.
Regardless of all of the potential, this chief in genomic devices has been within the development doldrums since their doomed acquisition of cancer-screening agency GRAIL $GRAL with revenues trending flat and even damaging since.
Because the market chief, Illumina ought to be discovering methods to develop their enterprise by means of promoting adjoining complimentary choices – like long-read sequencing.
The Lengthy-Learn Sequencing Alternative
Illumina devices carry out what’s known as “short-read sequencing” which, because the title implies, doesn’t paint a whole image of the genome. To grasp the whole genome you want “long-read sequencing” which is understandably dearer, however that’s the place all the small print could be discovered and fed to hungry AI algorithms for insights. Illumina developed their very own long-read providing which is described as “artificial” and never the identical kind supplied by the 2 most distinguished suppliers of such instruments – Oxford Nanpore $ONT.L and Pacific Biosciences $PACB.
A questionable total addressable market (TAM) for long-read sequencing is one thing we’ve talked about previously. That’s as a result of these instruments are predominantly utilized in analysis functions. However ultimately, we’d anticipate business functions to outpace analysis as everybody adopts the newest and biggest sequencing know-how, proper?
Not essentially. If short-read sequencing does the job, who’s going to spend the additional cash on long-read? Tech analysts will shortly level to how we’re now shifting from the $100 genome to a $10 genome in short-read sequencing. Whereas the identical dramatic price reductions might occur for long-read sequencing, all these Illumina short-read machines aren’t going to get replaced if firms are discovering them adequate for his or her operations. If it ain’t broke, don’t repair it.
Reasonably than speculating on the way forward for these two gene sequencing strategies, we are able to let the numbers do the speaking. Income development is all the time the bottom reality for the progress any know-how is making. And Oxford Nanopore has been checking the expansion packing containers. Under we’ve charted the expansion of their core providing (what they name life science analysis instruments or LSRT) over time.
Observe that COVID ushered in a short lived surge of income which masks the actual development of their core providing, so it’s helpful to disregard these one-time advantages. It’s all about promoting {hardware} and consumables that are seeing respectable development. There was a stutter step final 12 months which was blamed on a myriad of things however supplied up as a transition to extra constant future development. This appears to be the case primarily based on the expansion of use instances outdoors of simply analysis. (Extra on this in a bit.)
If firms need to do long-read sequencing, it’s turning into more and more doubtless they’ll be doing it on Oxford Nanopore {hardware}. That’s as a result of the one different possibility is at the moment experiencing some rising pains.
The PacBio vs Oxford Nanopore Duopoly
Oxford Nanopore and PacBio have a duopoly on the long-read instrumentation market proper now. That turned obvious again in 2018 when Illumina tried to amass PACB and regulators shot down the transaction due to monopoly issues. With Illumina’s artificial long-read providing not seeming to realize a lot traction, an funding in each these firms appears to nook the long-read alternative.
Nonetheless, the final time we checked out Pacific Biosciences, the corporate gave the impression to be surviving, not thriving. They have been burning gobs of money with income development shortly drying up. That also seems to be the case in the present day, with preliminary full-year 2025 earnings outcomes pointing to low single-digit income development after damaging double-digit income development in 2024. Under you’ll be able to see the place income development dripped off in early 2024 and hasn’t picked up since.
Quite a few instances revenues expectations weren’t met as the corporate cited funding constraints, fewer placements, and competitors.
When earnings are formally launched subsequent month the corporate ought to present steering for 2026 which they’ll in all probability strategy with warning given previous steering misses. New SPRQ-Nx sequencing chemistry implies that, “clients working at scale might see as a lot as a 40% discount from present prices, right down to a worth of lower than $300 per genome.” Let’s hope that retains being mirrored in stronger consumables development (i.e. clients use their devices extra) which got here in at almost 16% final 12 months. Sadly, that was offset by an 18% decline in instrument gross sales. “Service and different income” was up 35% final 12 months, however providers don’t scale like an instrument enterprise mannequin does. They’re additionally not as worthwhile, and PacBio’s gross margin has been steadily declining over time.
Ever because the development issues began, administration has been shifting their language extra in direction of surviving than thriving. They anticipated to burn $115 million of money in 2025 and have $330 million in money and receivables on the steadiness sheet. The clock is ticking with $645 million in senior notes coming due in 2028 and 2030. Our earlier conclusion hasn’t modified a bit. “We’re going to keep away from PACB till they’ll present a clearly possible path to optimistic working money flows which might reveal an economically viable long-read platform.” We’re solely considering leaders for any given theme. Oxford Nanopore appears to be the chief in long-read proper now with extra income, stronger income development, and a a lot stronger steadiness sheet than PacBio which provides them higher funding choices in the event that they want them.
Oxford Nanopore’s Success
In final 12 months’s piece on Oxford Nanopore we talked about monitoring progress in key markets corresponding to biopharma. In different phrases, we need to see income development coming from one thing apart from analysis. Oxford supplies three further income segments – scientific, biopharma, and utilized industrial – the expansion of which could be seen under (in USD hundreds of thousands):
Oxford plans to launch their 2025 leads to March, however within the meantime, we’re given preliminary numbers for assurance which mirror robust income development of about 25%. And it’s the place that development got here from that issues most. For the whole 12 months, Medical income grew by roughly 60%, BioPharma by roughly 30%, and Utilized Industrial by roughly 27%. Analysis income grew by roughly 15% in the course of the interval regardless of end-market funding pressures. It’s promising to see each phase that isn’t analysis rising quicker than analysis. Promoting analysis devices to establishments with fickle budgets means the corporate can be topic to a whole lot of volatility.
Different key metrics we mentioned to regulate included PromethION adoption charges, new large-scale manufacturing contracts, and actual scientific traction, which we touched on earlier. PromethION is Oxford’s flagship long-read DNA and RNA sequencing machine, constructed for real-time, large-scale functions like researching complicated ailments or analyzing genetic traits throughout giant populations. Distinction that to MinION, which is a handheld machine higher fitted to small reads. As we’d hoped, the dearer PromethION units are driving most of Oxford Nanopore’s development.
Relating to giant manufacturing contracts, Oxford Nanopore and Bio-Techne prolonged their biomanufacturing contract into 2032, centered on constructing instruments for the screening and prognosis of genetic problems. We’re not given particular numbers right here, so it’s onerous to know the way vital this partnership is.
Valuation and Runway
Issues seem like progressing as we’d hoped, however you wouldn’t guess it by trying on the firm’s valuation. With annualized income of £211 million GBP and a market cap of £1.57 billion GBP, Oxford Nanopore sports activities a easy valuation ratio of seven.4, proper in step with our catalog common. Regardless of the robust execution and double-digit income development, Oxford Nanopore inventory has a median valuation. Maybe buyers are involved in regards to the firm’s survivability.
When an organization achieves optimistic working money flows, buyers can breathe a sigh of aid. It’s now theoretically doable for a corporation to generate all of the money it wants with out having to promote fairness or increase debt. Oxford Nanopore says they need to “obtain breakeven” subsequent 12 months which suggests some sharp discount of their present money burn. The under “money bridge” exhibits how a lot money they burned by means of for the primary half of this 12 months, about half of which was from operations.
At that burn charge they need to have about 2.5 years runway left earlier than they should promote shares (dilute buyers) or tackle debt (they at the moment don’t have any long-term debt). Nonetheless, that doesn’t imply they gained’t want to boost capital. If the worth of long-read could be demonstrated throughout sufficient domains with acceptable pricing, maybe Oxford can develop a large enterprise whereas having fun with all the advantages that include being the dominant supplier of a needed software. If demand to scale requires capital, they could have a look at elevating debt or promoting shares on the highest valuation doable.
Conclusion
The long-read sequencing story appears to be on observe, however we have to see extra business development. Diversifying away from analysis can be a hurdle the corporate must clear earlier than buyers are keen to ascribe it a premium valuation. It would additionally show that long-read sequencing could be commercially viable within the face of cheaper short-read choices like these from Illumina. With two firms having a commanding market share of the long-read alternative, one appears to have the benefit proper now and that’s Oxford Nanopore.
